ANT-GROUP
13.6.2024 06:45:32 CEST | Business Wire | Press release
Ant Group (or “the Company”) today released its 2023 Sustainability Report, showcasing the Company’s significant progress since the introduction of its ESG strategy in 2022 and demonstrating its commitment to transparency and to its sustainable business practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612743798/en/
Technological Innovation (Graphic: Business Wire)
The report highlights noteworthy advancements across key areas, underpinned by four core pillars: Technological Innovation, Digital Inclusion, Green and Low-Carbon Development, and Open Ecosystem.
“Looking ahead, we are constantly reflecting on how to stay true to our original aspirations in this era of rapid change, continuously bringing about more small yet beautiful changes to the world,” said Eric Jing, Chairman & CEO of Ant Group. “Since our journey started from Alipay’s inception in 2004, technology-driven innovation has always been the fundamental force propelling our growth. It will play an even greater role in shaping our future.”
Technological Innovation
To drive innovation for consumers, small and micro-sized enterprises (SMEs) and partners, Ant Group has increased its investment in technology R&D for three consecutive years, reaching a record high of RMB 21.19 billion yuan (~ 2.92 billion USD) in 2023. Ant Group’s BaiLing Foundation Model, which was approved to serve the Chinese public in 2023, has been powering AI assistants that make it easier for users to access various life services on the Alipay platform, from smart life assistant, to smart healthcare manager and smart financial manager.
Digital Inclusion
By leveraging digital payment and finance innovation, Ant Group, together with its associate MYbank, have served more than 87 million SMEs as of 2023.
On the Alipay platform, thousands of Independent Software Vendors (ISVs) have developed more than 700 digital solutions for 4.27 million merchants, enabling them to seize more business opportunities through digital operations. In 2023, the annual transaction volume of merchant operated Alipay mini-programs grew by 68% year-on-year.
Green and Low-Carbon Development
By the end of 2023, Ant Group had achieved operation-wide carbon neutrality for three consecutive years, with a 43.19% reduction in absolute Scope 1 & 2 emissions compared to the 2020 baseline year. In accordance with standards such as the "Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Accounting and Reporting Standards" and the "Global Financial Industry Greenhouse Gas Accounting and Reporting Standards," Ant Group conducted the Company’s first comprehensive accounting for Scope 3 carbon emissions in 2023, covering 11 categories related to activities along Ant Group's value chain, which provides a scientific basis for further emission reduction initiatives.
Since its launch in 2016, Alipay Ant Forest has encouraged more than 690 million users to make everyday low-carbon choices. As a result, 475 million trees have been planted by local partners with financial support from the Company.
Open Ecosystem
To better connect travelers with merchants and facilitate cross-border commerce, more than 25 leading e-wallets and banking apps have adopted Alipay+, a suite of cross-border digital payment and digitalization technology solutions. Alipay+ enables their users to pay and travel like locals, bringing international businesses to over 88 million merchants worldwide. In addition, with its one World Account, WorldFirst has served one million SME traders to pay, connect, and manage money globally.
The 10x1000 Tech for Inclusion program has provided exchange and learning opportunities for 6,243 certified learners from over 100 countries and regions, of whom nearly half are women participants.
Ant Group, after establishing 19 sustainability issues with 3-year OKRs (Objectives and Key Results) and plans in 2022, has upgraded its governance and incentive system in line with global best practices. This includes linking senior management’s remuneration to the Company’s risk management and sustainability performance metrics.
In 2023, Ant Group used relevant Sustainability Accounting Standards Board(SASB) industry standards as a guiding reference for its sustainability reporting for the first time. Ant Group also bolstered its climate-related disclosures with reference to the International Sustainability Standards Board (ISSB) requirements, including detailing how its executives and senior management tackle climate-related decisions as well as the establishment of an early warning platform to monitor extreme weather's impact on business operations.
Note: All figures are as of December 31, 2023 unless otherwise specified. The 2023 Sustainability Report is available in Chinese. The English-language version will be available on Ant Group’s official website soon.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612743798/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom